Xeris Pharmaceuticals | XERS - Interest Expense On Debt


Xeris Pharmaceuticals reported $6.88M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Celltrion KRW 19B 1.96B Jun/2025
Cspc Pharmaceutical CNY 6.76M 3.43M Dec/2025
Deva Holding AS TRY 272.53M 69.04M Sep/2023
Dianthus Therapeutics USD 4.44M 263K Sep/2024
Divis Laboratories Ltd INR 60M 0 Jun/2026
Eli Lilly USD 316M 201.3M Sep/2026
Kangmei Pharma CNY 1.82M 150K Sep/2025
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
Laboratorios Farma EUR 699K 666.2K Jun/2025
Medical Developments International AUD 18K 3K Jun/2025
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Neuren Pharmaceuticals AUD 0 0 Jun/2024
Organigram Holdings CAD 179K 127K Mar/2025
Ovoca Bio EUR 7K 6K Jun/2022
Pacira USD 3.62M 77K Jun/2026
Perrigo USD 7.61B 373.8M Jun/2026
Pharma Mar EUR 117K 1.24M Sep/2025
Qiagen NV USD 10.02M 1.03M Jun/2026
Sartorius EUR 44.9M 4.6M Sep/2026
Sino Biopharmaceutical CNY 76.87M 114.23M Jun/2024
Supernus Pharmaceuticals USD 718K 1.6M Sep/2026
Tilray USD 6.7M 2.73M Jun/2025
Zealand Pharma A/S 7.07M 74K Dec/2025
Zz Pientze Pharmaceu CNY 46.05M 36.5M Jun/2025